rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Paul Bisaro

Director

Company insider

Files Form 4 as: Director, Keenova Therapeutics; Director, Myriad Genetics; Director, Zoetis; Director, TherapeuticsMD; Executive Chairman, Amneal Pharmaceuticals; President and CEO, Impax Laboratories; Exec Chairman, Allergan; Director, Zimmer Biomet Holdings.

Every Form 4 they filed

In numbers

Trades disclosed
298
Buys
7
Sells
32
Bought
$999K
Sold
$54.8M
Companies
10
Companies where not an officer
5
First trade
3 Jan 2006
Last trade
15 Jul 2026
Last filed
17 Jul 2026

Companies traded

Where they are an officer
AMRX Amneal PharmaceuticalsDirector, Officer · Pharmaceuticals · last 7 May 20191 buy · 0 sells
Impax LaboratoriesDirector, Officer · last 4 May 20180 buys · 0 sells
AllerganDirector, Officer · last 2 May 20181 buy · 2 sells
ActavisDirector, Officer · last 1 Oct 20130 buys · 1 sell
Barr PharmaceuticalsDirector, Officer, Other · last 23 Oct 20070 buys · 29 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Keenova TherapeuticsDirector · last 15 Jul 20261 buy · 0 sells
MYGN Myriad GeneticsDirector · Diagnostics & Labs · last 4 Jun 20261 buy · 0 sells
ZTS ZoetisDirector · Pharmaceuticals · last 13 May 20261 buy · 0 sells
TXMD TherapeuticsMDDirector · Biotechnology · last 29 Sep 20222 buys · 0 sells
ZBH Zimmer Biomet HoldingsDirector · Medical Devices · last 31 Mar 20170 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
02Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 17 Jul 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code A—4,406 at $0.00filing
15 Jul 2026filed 17 Jul 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code A—4,406 at $0.00filing
4 Jun 2026filed 5 Jun 2026MYGN Myriad GeneticsDiagnostics & LabsSEC FORM 4 Code A—59,701 at $0.00filing
4 Jun 2026filed 5 Jun 2026MYGN Myriad GeneticsDiagnostics & LabsSEC FORM 4 Code A—59,701 at $0.00filing
2 Jun 2026filed 4 Jun 2026Keenova TherapeuticsSEC FORM 4 Code M—2,685filing
2 Jun 2026filed 4 Jun 2026Keenova TherapeuticsSEC FORM 4 Code F—619filing
2 Jun 2026filed 4 Jun 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code D—2,197filing
2 Jun 2026filed 4 Jun 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code D—2,197filing
2 Jun 2026filed 4 Jun 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code M—2,685 at $0.00filing
2 Jun 2026filed 4 Jun 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code M—2,685 at $0.00filing
2 Jun 2026filed 4 Jun 2026Keenova TherapeuticsSEC FORM 4 Code M—2,685filing
2 Jun 2026filed 4 Jun 2026Keenova TherapeuticsSEC FORM 4 Code F—619filing
14 May 2026filed 14 May 2026MYGN Myriad GeneticsDiagnostics & LabsSEC FORM 4 Bought$28K7,500 at $3.69filing
14 May 2026filed 14 May 2026MYGN Myriad GeneticsDiagnostics & LabsSEC FORM 4 Bought$28K7,500 at $3.69filing
13 May 2026filed 13 May 2026ZTS ZoetisPharmaceuticalsSEC FORM 4 Bought$152K2,000 at $75.88filing
13 May 2026filed 13 May 2026ZTS ZoetisPharmaceuticalsSEC FORM 4 Bought$152K2,000 at $75.88filing
23 Feb 2026filed 25 Feb 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code A—3,984 at $0.00filing
23 Feb 2026filed 25 Feb 2026Keenova Therapeuticsoption or derivativeSEC FORM 4 Code A—3,984 at $0.00filing
19 Feb 2026filed 23 Feb 2026ZTS ZoetisPharmaceuticalsSEC FORM 4 Code M—1,619filing
19 Feb 2026filed 23 Feb 2026ZTS Zoetisoption or derivative · PharmaceuticalsSEC FORM 4 Code M—1,619.333filing

Sectors

Health Care5
Not placed34

Buys in green, sells in red, by the company’s sector.

Related people

J. Kevin BuchiDirector · Director at Amneal Pharmaceuticals, filing Form 4 there in the last year
Andrew S. BoyerExecutive Vice President · Executive Vice President at Amneal Pharmaceuticals, filing Form 4 there in the last year
John KielyDirector · Director at Amneal Pharmaceuticals, filing Form 4 there in the last year
Nikita ShahExecutive Vice President · Executive Vice President at Amneal Pharmaceuticals, filing Form 4 there in the last year
Jason B. DalyEVP, Chief Legal Officer · EVP, Chief Legal Officer at Amneal Pharmaceuticals, filing Form 4 there in the last year
Gilbert Ray Cisneros, Jr.Representative, CA-31 · Also traded ZTS in the last 90 days
Donald J. TrumpPresident · Also traded ZTS in the last 90 days